Advocates and lawmakers spar over governor appointees on insurer boards in H.585

Lawmakers and advocates clashed at a Senate Finance Committee hearing April 8 over provisions in H.585 that would allow gubernatorial appointees to serve on certain nonprofit insurer boards.

Jessica Vargas, vice president of public affairs for Planned Parenthood of Northern New England, told the committee she opposes the proposal, saying it would “politicize our healthcare delivery.” She said extending gubernatorial appointment power to nonprofit insurers risks influencing benefit design, utilization management and network policies in ways that could restrict access to reproductive and other legally protected care.

“Board governance can shape how aggressively an insurer complies with or constrains those protections,” Vargas said, warning that political appointees could pressure nonprofit insurers “to end advocacy or policies that may decrease access to legally protected healthcare services.”

Representatives of the bill and some lawmakers countered that the provision is narrowly targeted at a specific corporate form. Representative Elizabeth Black and others said the measure is designed to address a unique circumstance: an insurer whose near‑insolvency in late 2023 threatened broad disruption in Vermont’s health system. “This is an insurance company that by most measures touches at least half of Vermonters,” Black said, urging the committee to weigh system stability.

Lawmakers and witnesses debated whether adding one or two public representatives would materially prevent financial collapse or whether improved regulation would be a better solution. Committee members asked Department of Financial Regulation (DFR) officials to explain whether regulatory actions missed warning signs before the 2023 claim surge and whether board appointments are the appropriate remedy.

Supporters of the change said the provision is constrained by statute: it applies to nonprofit hospital service corporations and would not be a general grant of appointment power to other nonprofits. Opponents, including nonprofit and reproductive‑health representatives, said the delegation risks setting a precedent that could be used by future governors to influence private governance and could chill advocacy and medical decision‑making inside insurers.

The committee signaled it will spend extended time on the governance sections, asking DFR to provide more context on regulatory oversight and the rationale for board representation. The hearing was recessed for a break with further discussion on the governance provisions expected when testimony resumes.